Results 41 to 50 of about 1,413,485 (300)

Community pharmacists’ measurement of health-related quality of life for breast cancer with positive hormone receptors: A prospective observational study

SAGE Open Medicine, 2023
Objectives: Many patients with hormone-receptor positive breast cancer undergo prolonged treatment. However, the long-term patient quality of life assessment has not been examined.
Takenori Ichimura, Hisanaga Nomura, Hisanori Shimizu   +2 more
doaj   +1 more source

Personalized Selumetinib Dosing in Pediatric Neurofibromatosis Type 1: Insights From a Pilot Therapeutic Drug Monitoring Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács, Zoltán Köllő, Balázs Gellért Karvaly, Mahmoud Obeidat, Rita Nagy, Péter Hegyi, Brigitta Teutsch, Eszter Tuboly, Miklós Garami   +8 more
wiley   +1 more source

Income-related inequality in life-years and quality-adjusted life-years [PDF]

Journal of Health Economics, 2000
We estimate the income-related inequality in Sweden with respect to life-years and quality-adjusted life-years (QALYs). We use a large data set from Sweden with over 40,000 individuals followed up for 10-16 years, to estimate the survival and quality-adjusted survival in different income groups.
Gerdtham, Ulf-G., Johannesson, Magnus
openaire   +3 more sources

Sirolimus for Extracranial Arteriovenous Malformations: A Scoping Review of the Evidence in Syndromic and Non‐Syndromic Cases

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Arteriovenous malformations (AVMs) are rare, high‐flow, vascular anomalies that can occur either sporadically or as part of a genetic syndrome. AVMs can progress with serious morbidity and even mortality if left unchecked. Sirolimus is an mTOR inhibitor that is effective in low‐flow vascular malformations; however, its role in AVMs is unclear.
Will Swansson, Ingrid Winship, Gary Hammerschlag, Laura Scardamaglia   +3 more
wiley   +1 more source

Financial Burden Associated With Hospitalisation Among Families of Childhood Brain Tumours in Australia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Families of children with cancer experience significant financial strain, even with universal healthcare. Indirect costs, such as productivity losses and non‐medical expenses, are rarely included in economic evaluations, and little is known about how effectively financial aid programmes alleviate this burden. Childhood brain tumours
Megumi Lim, Natalie Bradford, David Brain, Sameera Senanayake, Sanjeewa Kularatna, Kate Young, Christine Cashion, Tim Hassall, Susanna Cramb   +8 more
wiley   +1 more source

Pharmacoeconomic analysis of the use of tocilizumab in therapy for rheumatoid arthritis:imitation simulation

Научно-практическая ревматология, 2010
Heavy economic expenses for treatment with genetic engineering biologicals (GEB) in patients with rheumatoid arthritis (RA) determine what strategies are most optimal in terms of both their clinical efficiency and economic constituent should be sought ...
Dmitry Vladimirovich Goryachev, Sh F Erdes, E L Nasonov   +2 more
doaj   +1 more source

Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study

BMC Health Services Research, 2023
Background The incidence and mortality rates of patients with chronic lymphocytic leukemia (CLL) in China have recently increased. This study performed a long-term economic evaluation of the first-line treatment strategies ibrutinib (IB) or bendamustine (
Yuan Hong, Xichuang Chen, Yuanquan Hong, Xingfang Xiao, Yan Wang, Xiaohong You, Jingyi Mi, Tao Zhou, Panpan Zheng, Zhihu Huang   +9 more
doaj   +1 more source

Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK

ERJ Open Research, 2021
UK management costs for COPD, estimated at £1.9 billion/year, are rising. In the FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) study, single-inhaler triple therapy with ...
Elisabeth Fenwick, Alan Martin, Melanie Schroeder, Stuart J. Mealing, Oyinkansola Solanke, Nancy Risebrough, Afisi S. Ismaila   +6 more
doaj   +1 more source

Pulmonary rehabilitation : insight into current trends [PDF]

, 2010
Pulmonary rehabilitation is a widely accepted therapeutic tool used to improve the quality of life and functional capacity of individuals with chronic lung disease.
Montefort, Stephen, Sciriha, Anabel
core  

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source